Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Assets (2016 - 2025)

Regenxbio (RGNX) has 12 years of Current Assets data on record, last reported at $281.3 million in Q4 2025.

  • For Q4 2025, Current Assets rose 1.18% year-over-year to $281.3 million; the TTM value through Dec 2025 reached $281.3 million, up 1.18%, while the annual FY2025 figure was $281.3 million, 1.18% up from the prior year.
  • Current Assets reached $281.3 million in Q4 2025 per RGNX's latest filing, down from $332.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $518.8 million in Q4 2021 and bottomed at $278.0 million in Q4 2024.
  • Average Current Assets over 5 years is $386.6 million, with a median of $384.0 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 47.42% in 2021, then fell 20.78% in 2025.
  • A 5-year view of Current Assets shows it stood at $518.8 million in 2021, then decreased by 19.82% to $416.0 million in 2022, then fell by 19.47% to $335.0 million in 2023, then decreased by 17.01% to $278.0 million in 2024, then rose by 1.18% to $281.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $281.3 million in Q4 2025, $332.0 million in Q3 2025, and $373.8 million in Q2 2025.